Table 1 Baseline characteristics of included gastric cancer patients
Variable | Training set (n = 307) | Validation set (n = 153) | P | |
|---|---|---|---|---|
Age | 59.18 ± 10.12 | 59.22 ± 10.46 | 0.802 | |
Sex | Male | 207 (67.43) | 100 (65.36) | 0.657 |
Female | 100 (32.57) | 53 (34.64) | ||
BMI | 22.38 (20.51–24.91) | 22.47 (20.18–24.54) | 0.712 | |
Location | Esophagogastric junction | 108 (35.18) | 58 (37.91) | 0.566 |
Non-Esophagogastric junction | 199 (64.82) | 95 (62.09) | ||
Tumor size, cm | 5.38 ± 2.07 | 5.71 ± 3.02 | 0.478 | |
Tumor differentiation | Well+Moderately differentiated | 111 (36.16) | 55 (35.95) | 0.965 |
Poorly differentiated+ Signet ring cell | 196 (63.84) | 98 (64.05) | ||
cT stage | T2 + T3 | 97 (31.60) | 45 (29.41) | 0.633 |
T4 | 210 (68.40) | 108 (70.59) | ||
cN stage | N0 | 60 (19.54) | 40 (26.14) | 0.106 |
N+ | 247 (80.46) | 113 (73.86) | ||
Borrmann classification | I + II | 88 (28.66) | 44 (28.76) | 0.983 |
III + IV | 219 (71.33) | 109 (71.24) | ||
Blood type | Type A | 88 (28.66) | 46 (30.07) | 0.883 |
Type B | 90 (29.32) | 42 (27.45) | ||
Type AB | 30 (9.77) | 18 (11.76) | ||
Type O | 99 (32.25) | 47 (30.72) | ||
CEA, ng/mL | 9.14 ± 10.12 | 10.21 ± 11.37 | 0.375 | |
CA724, U/mL | 3.61 (1.57–10.52) | 3.55 (1.50–10.33) | 0.446 | |
CA125, U/mL | 13.96 ± 7.03 | 13.94 ± 7.22 | 0.743 | |
CA199, U/mL | 37.64 ± 42.18 | 38.05 ± 57.32 | 0.556 | |
Albumin, g/L | 42.13 ± 3.08 | 41.97 ± 3.77 | 0.289 | |
PLT, 109/L | 218.76 ± 28.40 | 214.49 ± 52.78 | 0.472 | |
Lymphocyte, 109/L | 1.58 ± 0.42 | 1.58 ± 0.46 | 0.943 | |
PLR | 135.76 (94.88–182.89) | 136.27 (104.42–182.73) | 0.575 | |
Neutrophil cell, 109/L | 3.60 ± 1.31 | 3.61 ± 1.44 | 0.667 | |
Monocyte, 109/L | 0.42 ± 0.15 | 0.41 ± 0.17 | 0.782 | |
NMR | 8.62 (6.62–10.64) | 8.58 (6.50–10.31) | 0.455 | |
NLR | 2.24 (1.58–2.94) | 2.24 (1.60–2.89) | 0.889 | |
MSI | H | 21 (6.84) | 12 (7.84) | 0.695 |
S/L | 286 (93.16) | 141 (92.16) | ||
Smoking history | yes | 110 (35.83) | 60 (39.22) | 0.479 |
no | 197 (64.17) | 93 (60.78) | ||